Holmberg Christine, Waters Erika A, Whitehouse Katie, Daly Mary, McCaskill-Stevens Worta
Berlin School of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany (CH, KW)
Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA (EAW)
Med Decis Making. 2015 Nov;35(8):1010-22. doi: 10.1177/0272989X15594382. Epub 2015 Jul 16.
Decision-making experts emphasize that understanding and using probabilistic information are important for making informed decisions about medical treatments involving complex risk-benefit tradeoffs. Yet empirical research demonstrates that individuals may not use probabilities when making decisions.
To explore decision making and the use of probabilities for decision making from the perspective of women who were risk-eligible to enroll in the Study of Tamoxifen and Raloxifene (STAR).
We conducted narrative interviews with 20 women who agreed to participate in STAR and 20 women who declined. The project was based on a narrative approach. Analysis included the development of summaries of each narrative, and thematic analysis with developing a coding scheme inductively to code all transcripts to identify emerging themes.
Interviewees explained and embedded their STAR decisions within experiences encountered throughout their lives. Such lived experiences included but were not limited to breast cancer family history, a personal history of breast biopsies, and experiences or assumptions about taking tamoxifen or medicines more generally.
Women's explanations of their decisions about participating in a breast cancer chemoprevention trial were more complex than decision strategies that rely solely on a quantitative risk-benefit analysis of probabilities derived from populations In addition to precise risk information, clinicians and risk communicators should recognize the importance and legitimacy of lived experience in individual decision making.
决策专家强调,理解和运用概率信息对于在涉及复杂风险效益权衡的医疗治疗中做出明智决策至关重要。然而,实证研究表明,个体在做决策时可能不会使用概率。
从有资格参与他莫昔芬与雷洛昔芬研究(STAR)的女性的角度,探讨决策制定以及决策中概率的运用。
我们对20名同意参与STAR的女性和20名拒绝参与的女性进行了叙述性访谈。该项目基于叙述方法。分析包括编写每个叙述的摘要,以及进行主题分析,通过归纳制定编码方案对所有访谈记录进行编码,以识别新出现的主题。
受访者将她们参与STAR的决策置于其一生所经历的各种事情中进行解释和阐述。这些生活经历包括但不限于乳腺癌家族史、个人乳房活检史,以及服用他莫昔芬或一般药物的经历或假设。
女性对参与乳腺癌化学预防试验的决策解释,比单纯依赖对群体概率进行定量风险效益分析的决策策略更为复杂。除了精确的风险信息外,临床医生和风险沟通者应认识到生活经历在个体决策中的重要性和合理性。